Navigation Links
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.

"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) stud
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
4. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
5. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Thousands of people will peacefully demonstrate their frustration ... epidemic at dozens of rallies across the country today. ... the United States has experienced skyrocketing rates ... heroin, yet the President has never once spoken publicly ... to President Obama , rally organizers compared his failure ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – a ... up with fellow South Walton property management company, 360 Blue, in support ... remote parts of the world. The two companies will collect any unopened food items ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... The Lisle ... Firm Partner William Scott has been nominated by his peers to earn a “Leading ... than five percent of attorneys in the state of Illinois. The nomination process is ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
(Date:8/31/2015)... ... ... Neuropsychiatric Disease and Treatment has published the ... phototherapy ”. , As corresponding author Dr Theodore Henderson says “These findings herald ... palliative treatments only - and now we have shown real clinical and neurophysiological ...
(Date:8/31/2015)... ... 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine ... Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot ...
Breaking Medicine News(10 mins):Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2
... can be used to measure cardiac function and has ... are limited, a preliminary study indicates. , CT coronary ... and function; however, CT coronary angiography uses a high ... nuclear medicine examinations, can evaluate structure and function with ...
... production is controlled could lead to improvements in the ... Australian medical researchers. , The findings are reported in ... American Society of Hematology and the worlds premier hematology ... Western Australian Institute for Medical Research (WAIMR) Director Peter ...
... of money, human resources, analysis concludes , , FRIDAY, ... countries most in need of improving mother and child ... meeting internationally set goals over the past three years, ... Countdown to 2015 for Maternal, Newborn and Child Survival, ...
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the ,Company,) ... device company that develops, manufactures and markets ... ultrasound tumor,therapy systems, today announced that it ... fourth quarter and fiscal year ended March ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Monday, April 28, 2008 at approximately,4:00 p.m. Eastern Time ... at 4:30 p.m. ET. Henry L. Nordhoff, chairman and ... and,chief financial officer, will host the call., The ...
... finds Internet searches provide more on ,how to, than ,how ... A new British study says that people surfing the Web ... that encourage the act rather than offering help and support. ... entered a dozen search terms, one at a time, into ...
Cached Medicine News:Health News:Twin findings raise hopes of improved anemia treatments 2Health News:Few Countries on Track to Curb Maternal, Child Mortality Rates 2Health News:Few Countries on Track to Curb Maternal, Child Mortality Rates 3Health News:China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008 2Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Suicide Data on Web Mostly Not Preventive 2
... monitor elevates bedside glucose testing to a ... the quality of central laboratory testing. ... strip technology. Current glucose strips use ... system measures and corrects hematocrit interference as ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... BreatheX is a wearable CPAP (Continuous Positive ... sleep apnea. The lightweight BreatheX CPAP device ... with its built-in, rechargeable battery, and is ... no longer need to be "plugged in ...
Paraffin Block Storage System...
Medicine Products: